Key result
Customized P-derived peptides (PFrs) exhibited potent inhibitory effects against paramyxoviruses (HPIV3, MeV, MuV) with IC50 values below 100 nM and minimal cytotoxicity.
Why the study?
Phosphoprotein-derived peptides were shown to inhibit RSV replication, prompting investigation into extending this targeting of P oligomerization to paramyxoviruses.
Effect estimate: IC50 < 100 nM
Customized P-derived peptides targeting P protein oligomerization demonstrate potent in vitro antiviral activity against paramyxoviruses, suggesting a potential broad-spectrum antiviral strategy.
Supports further exploration of P protein-targeted peptides; leaves open translation from in vitro data to clinical use.
In Mononegavirales, phosphoproteins (P) are essential polymerase cofactors, forming oligomers and interacting with viral components to facilitate replication. Previous studies have demonstrated that a P-derived peptide (PFr) from the respiratory syncytial virus (RSV), containing the oligomerization domain (OD) and C-terminal domain (CTD), effectively inhibits RSV replication. Here, we extend this approach to paramyxoviruses, including HPIV3, MeV and MuV. Customized PFrs exhibited potent inhibitory effects against their respective viruses, with IC50 values below 100 nM, while showing minimal cytotoxicity. These findings highlight the potential of targeting P oligomerization as a broad-spectrum antiviral strategy for paramyxoviruses and other mononegaviruses.
No takes yet. Share an insight, caveat, or question.
Hara et al. (2024) studied Paramyxovirus infection (HPIV3, MeV, MuV). Customized P-derived peptides (PFrs) was evaluated on Viral replication inhibition (IC50) (IC50 < 100 nM). Customized P-derived peptides (PFrs) exhibited potent inhibitory effects against paramyxoviruses (HPIV3, MeV, MuV) with IC50 values below 100 nM and minimal cytotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: